Tags : Malignancy

Biosimilars Regulatory

Mundipharma Receives EU Approval for Pelmeg (Pegfilgrastim, Biosimilar)

Shots: Pelmeg (Pegfilgrastim, Biosimilar) is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic CT for malignancy CHMP recommends Pelmeg based on the results from pharmacodynamics, pharmacokinetics, and immunogenicity comparisons with Neulasta Pelmeg is Granulocyte-colony stimulating factor (G-CSF) biosimilar that stimulates bone marrow to produce more […]Read More